Nexgard 11 mg for dogs between 2 and 4 kg 3 chewable tablets
Treatment of tick and flea infestations in dogs
NexGard 11 mg chewable tablets for dogs 2–4 kg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
NexGard: Afoxolaner (mg)
chewable tablets for dogs 2–4 kg: 11.3
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Mottled red to reddish brown, circular shaped (tablets for dogs 2–4 kg) or rectangular shaped (tablets for dogs >4–10 kg, tablets for dogs >10–25 kg and tablets for dogs >25–50 kg).
4. CLINICAL PARTICULARS
4.1 Target species
4.2 Indications for use, specifying the target species
Treatment of flea infestation in dogs (Ctenocephalides felis and C. canis) for at least 5 weeks. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Treatment of tick infestation in dogs (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus). One treatment kills ticks for up to one month.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
4.4 Special warnings for each target species
Parasites need to start feeding on the host to become exposed to afoxolaner; therefore the risk of the transmission of parasite borne diseases cannot be excluded.
4.5 Special precautions for use
Special precautions for use in animals
In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 2 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
To prevent children from getting access to the veterinary medicinal product, remove only one chewable tablet at a time from the blister. Return the blister with the remaining chewable tablets into the carton.
Wash hands after handling the product.
4.6 Adverse reactions (frequency and seriousness)
Mild gastrointestinal effects (vomiting, diarrhoea), pruritus, lethargy, or anorexia may be observed on very rare occasions. Theses occurrences are generally self-limiting and of short duration.
The frequency of adverse reactions is defined using the following convention:
very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
common (more than 1 but less than 10 animals in 100 animals)
uncommon (more than 1 but less than 10 animals in 1,000 animals)
rare (more than 1 but less than 10 animals in 10,000 animals)
very rare (less than 1 animal in 10,000 animals, including isolated reports).
4.7 Use during pregnancy, lactation or lay
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic effects, or any adverse effect on the reproductive capacity of males and females.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in breeding dogs. Use only according to the benefit-risk assessment by the responsible veterinarian.
4.8 Interaction with other medicinal products and other forms of interaction
4.9 Amounts to be administered and administration route
For oral use.
The product should be administered at a dose of 2.7–6.9 mg/kg bodyweight in accordance with the following table:
Bodyweight of dog (kg): Strength and number of chewable tablets to be administered
2–4: 1 NexGard 11 mg
>4–10: 1 NexGard 28 mg
>10–25: 1 NexGard 68 mg
>25–50: 1 NexGard 136 mg
For dogs above 50 kg bodyweight, use an appropriate combination of chewable tablets of different/same strengths. The tablets should not be divided.
Method of administration:
The tablets are chewable and palatable to most dogs. If the dog does not accept the tablets directly they may be administered with food.
Monthly intervals throughout the flea and/or tick seasons, based on local epidemiological situations.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No adverse reactions were observed in healthy Beagle puppies over 8 weeks of age when treated with 5 times the maximum dose repeated 6 times at intervals of two to four weeks.
4.11 Withdrawal period
5. PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Ectoparasiticides for systemic use.
ATCvet code: QP53BX04.
5.1 Pharmacodynamic properties
Afoxolaner is an insecticide and acaricide belonging to the isoxazoline family. Afoxolaner acts at ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes. This results in uncontrolled activity of the central nervous system and death of insects or acarines. The selective toxicity of afoxolaner between insect/acarines and mammals may be inferred by the differential sensitivity of the insect/acarines’ GABA receptors versus mammalian receptors.
Afoxolaner is active against adult fleas as well as several tick species such as Dermacentor reticulatus and D. variabilis, Ixodes ricinus and I. scapularis, Rhipicephalus sanguineus, Amblyomma americanum and Haemaphysalis longicornis.
NexGard kills fleas within 8 hours and ticks within 48h.
The product kills fleas before egg production and therefore prevents household contamination.
5.2 Pharmacokinetic particulars
After oral administration in dogs, afoxolaner was shown to have high systemic absorption following administration. The absolute bioavailability was 74%. The mean maximum concentration (Cmax) was 1,655 ± 332 ng/ml in plasma at 2–4 hours (Tmax) after a 2.5 mg/kg afoxolaner dose.
Afoxolaner distributes into tissues with a volume of distribution of 2.6 ± 0.6 l/kg and a systemic clearance value of 5.0 ± 1.2 ml/hr/kg. The terminal plasma half-life is approximately 2 weeks in most dogs; however, half-life of afoxolaner can differ between dogs (e.g. in one study, t½ in Collies at 25 mg/kg bodyweight was up to 47.7 days) with no effect on safety. In-vitro experiments demonstrated that P-glycoprotein efflux does not occur, confirming that afoxolaner is not a substrate for the P-glycoprotein transporters.
Afoxolaner in the dog is metabolized to more hydrophilic compounds and then eliminated. The metabolites and parent are eliminated from the body via urinary and biliary excretion with the majority eliminated in the bile. No evidence of enterohepatic recycling has been observed.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Soy protein fines
Braised beef flavouring
Macrogol 15 hydroxystearate
6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 30 months.
6.4 Special precautions for storage
This veterinary medicinal product does not require any special storage conditions.